^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20-targeted CAR-T immunotherapy

    Related drugs:
    6d
    A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases (clinicaltrials.gov)
    P1, N=37, Not yet recruiting, Wuhan Union Hospital, China
    New P1 trial
    |
    LCAR-AIO
    7d
    A Study of LCAR-AIO in Subjects with Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=38, Recruiting, Nanjing Legend Biotech Co.
    New P1 trial
    |
    LCAR-AIO
    26d
    LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=12, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jaypirca (pirtobrutinib) • CAR-20/19-T Cells
    27d
    PRO00037171: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Medical College of Wisconsin | Trial completion date: Jan 2025 --> Jun 2028 | Trial primary completion date: Jan 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CAR-20/19-T Cells
    1m
    Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=54, Recruiting, Sumithira Vasu | N=36 --> 54
    Enrollment change • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD20 positive
    |
    cyclophosphamide • fludarabine IV • Anti-CD19/CD20/CD22 CAR T-Cells
    1m
    CRC-403: A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov)
    P1/2, N=15, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting | N=50 --> 15 | Trial primary completion date: Aug 2024 --> Aug 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    bbT369
    2ms
    A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, ImmPACT Bio | N=30 --> 0 | Trial completion date: Feb 2027 --> Jan 2025 | Recruiting --> Withdrawn | Trial primary completion date: Feb 2027 --> Jan 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    2ms
    A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. (PubMed, Blood)
    Patients with CD19 and/or CD20-positive r/r B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2/d; fludarabine: 30 mg/m2/d) followed by an intravenous dose of prizlon-cel...Prizlon-cel showed a favorable safety profile and a high and durable response in patients with r/r B-NHL, suggesting a promising treatment option for patients with r/r B-NHL. (ClinicalTrials.gov number: NCT04317885, NCT04655677, NCT04696432, NCT04693676).
    P1 data • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    cyclophosphamide • fludarabine IV • prizloncabtagene autoleucel (JNJ-4496)
    2ms
    A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=34, Recruiting, Wuhan Union Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    LCAR-AIO
    2ms
    A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov)
    P1, N=20, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2027 --> May 2039
    Trial completion date
    |
    JNJ-9530
    2ms
    A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas (clinicaltrials.gov)
    P1, N=1, Terminated, Astellas Pharma Global Development, Inc. | N=21 --> 1 | Trial completion date: Aug 2031 --> Dec 2024 | Initiation date: Apr 2024 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Dec 2024; The termination of the study was a business decision made by the sponsor.
    Enrollment change • Trial completion date • Trial initiation date • Trial termination • Trial primary completion date
    2ms
    A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov)
    P1, N=9, Recruiting, Affiliated Hospital of Nantong University
    New P1 trial
    |
    EGFR mutation • IDH1 mutation • EGFR amplification • CDKN2A deletion
    |
    cyclophosphamide • fludarabine IV
    3ms
    A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=230, Recruiting, Janssen Research & Development, LLC | N=104 --> 230
    Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    3ms
    A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=12, Recruiting, Shanghai Cell Therapy Group Co.,Ltd
    New P1 trial • CAR T-Cell Therapy
    |
    cyclophosphamide
    3ms
    DALY 2-EU: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (clinicaltrials.gov)
    P2, N=168, Active, not recruiting, Miltenyi Biomedicine GmbH | Trial completion date: Jul 2027 --> Jul 2029
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)
    4ms
    US Zamto-cel Autoimmune Diseases (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Miltenyi Biomedicine GmbH
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • zamtocabtagene autoleucel (MB-CART2019.1)
    4ms
    A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects with Relapsed or Refractory B-Cell Hematological Malignancies (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, GenomeFrontier Therapeutics TW Co., Ltd.
    New P1 trial • CAR T-Cell Therapy
    4ms
    MB-CART20.1 Lymphoma (clinicaltrials.gov)
    P1/2, N=10, Completed, Miltenyi Biomedicine GmbH | Active, not recruiting --> Completed | N=19 --> 10
    Trial completion • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    MB-CART20.1
    4ms
    Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Miltenyi Biomedicine GmbH | Not yet recruiting --> Recruiting
    Enrollment open • Gene therapy
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    4ms
    CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (clinicaltrials.gov)
    P1, N=24, Suspended, Medical College of Wisconsin | Recruiting --> Suspended
    Trial suspension
    |
    CD20 positive
    |
    CAR-20/19-T Cells
    4ms
    ELEVATION: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=112, Recruiting, Shanghai AbelZeta Ltd. | Phase classification: P1b/2 --> P1/2 | N=72 --> 112 | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Mar 2027 --> Oct 2025
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    prizloncabtagene autoleucel (JNJ-4496)
    5ms
    Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. (PubMed, RMD Open)
    We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.
    Journal • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    5ms
    A Study of LCAR-AIO in Subjects with Relapsed/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Wuhan Union Hospital, China
    New P1 trial
    |
    LCAR-AIO
    5ms
    Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma. (PubMed, Front Immunol)
    In conclusion, the CliniMACS Prodigy® platform is well suited for decentralized POC manufacturing of anti-CD20 CAR T cells and may be likewise applicable for the rapid and automated manufacturing of CAR T cells directed against other targets. https://clinicaltrials.gov/study/NCT03893019?cond=Melanoma&term=NCT03893019&rank=1, identifier NCT03893019.
    Journal • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    MB-CART20.1
    6ms
    CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=4, Terminated, Medical College of Wisconsin | All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CAR20.19.22 T
    6ms
    Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Immune cell
    |
    CD20 (Membrane Spanning 4-Domains A1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
    |
    cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab)
    7ms
    INVISE: Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Treatment (clinicaltrials.gov)
    P1, N=30, Recruiting, Interius BioTherapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    7ms
    JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, RenJi Hospital
    New P1 trial
    7ms
    A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov)
    P1, N=20, Recruiting, Janssen Research & Development, LLC | N=92 --> 20
    Enrollment change • CAR T-Cell Therapy
    |
    JNJ-9530
    7ms
    INVISE: Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Treatment (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Interius BioTherapeutics Inc.
    New P1 trial
    8ms
    Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects With Relapsed/Refractory Lymphoma (clinicaltrials.gov)
    P1, N=9, Recruiting, Shanghai First Song Biotechnology Co., LTD
    New P1 trial • CAR T-Cell Therapy
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    cyclophosphamide • fludarabine IV
    8ms
    An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=9, Recruiting, Fudan University
    New P1 trial
    |
    cyclophosphamide
    8ms
    IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P1, N=36, Recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    cyclophosphamide
    8ms
    MB106-CD20-001: Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL (clinicaltrials.gov)
    P1/2, N=20, Terminated, Mustang Bio | N=287 --> 20 | Trial completion date: Sep 2026 --> Apr 2024 | Recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Apr 2024; Business reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MB-106
    8ms
    Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. (clinicaltrials.gov)
    P=N/A, N=3, Terminated, Mustang Bio | N=331 --> 3 | Trial completion date: Jul 2041 --> Apr 2024 | Enrolling by invitation --> Terminated | Trial primary completion date: Apr 2041 --> Apr 2024; Business Reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • CAR T-Cell Therapy
    |
    MB-106 • MB-102
    8ms
    DALY 2-EU: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (clinicaltrials.gov)
    P2, N=168, Active, not recruiting, Miltenyi Biomedicine GmbH | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)
    8ms
    Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) (clinicaltrials.gov)
    P1/2, N=12, Completed, Miltenyi Biomedicine GmbH | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> May 2024
    Trial completion • Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    8ms
    LONGSAFE: Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Miltenyi Biomedicine GmbH
    New trial • Gene therapy
    |
    MB-CART 19.1 • MB-CART20.1 • zamtocabtagene autoleucel (MB-CART2019.1)
    8ms
    DALY PED: Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With Relapsed or Refractory B-Cell Neoplasms (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Miltenyi Biomedicine GmbH
    New P2 trial
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    8ms
    IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P1, N=36, Enrolling by invitation, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    cyclophosphamide
    9ms
    A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas (clinicaltrials.gov)
    P1, N=21, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: May 2031 --> Aug 2031 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    9ms
    IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New P1 trial
    |
    cyclophosphamide